Verzenios यूरोपीय संघ - अंग्रेज़ी - EMA (European Medicines Agency)

verzenios

eli lilly nederland b.v. - abemaciclib - breast neoplasms - antineoplastic agents - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5.1).in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist.advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.

VERZENIO TABLET कनाडा - अंग्रेज़ी - Health Canada

verzenio tablet

eli lilly canada inc - abemaciclib - tablet - 50mg - abemaciclib 50mg - antineoplastic agents

VERZENIO TABLET कनाडा - अंग्रेज़ी - Health Canada

verzenio tablet

eli lilly canada inc - abemaciclib - tablet - 100mg - abemaciclib 100mg - antineoplastic agents

VERZENIO TABLET कनाडा - अंग्रेज़ी - Health Canada

verzenio tablet

eli lilly canada inc - abemaciclib - tablet - 150mg - abemaciclib 150mg - antineoplastic agents